Navigation Links
ChanTest hires Chris Mathes as Chief Commercial Officer
Date:8/17/2012

CLEVELAND, Aug. 17, 2012 /PRNewswire/ -- Today ChanTest announces the hiring of Chris Mathes, Ph.D., M.B.A. to lead its business into a new era. Mathes starts September 1st as Chief Commercial Officer (CCO) and will oversee all sales, marketing and customer relations activities at ChanTest. He will also contribute to the forward looking and strategic guidance of ChanTest as a global player in the CRO industry.

(Photo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO )

"Chris is a real ion channel guy," said Dr. Arthur "Buzz" Brown, CEO, President & Founder of ChanTest. "As CCO, he brings a unique mix of science and business to our company in order to make ChanTest's interface to the world even better."

Dr. Mathes has a Ph.D. in Neuroscience from UCLA and an MBA from Rutgers University. He has published several ion channel papers in peer reviewed journals over the past two decades.  In the last 10 years, Mathes has been a pioneer in the development and implementation of automated patch clamp systems for ion channel safety testing and drug discovery. 

"I'm really excited about this opportunity at ChanTest," Mathes said. "ChanTest is already the market leading ion channel CRO. My goal is to further enhance the brand and to expand the business.  I want to make sure that every pharmaceutical or biotech lab in the world accesses the ion channel and scientific expertise available at ChanTest."

About ChanTest Corporation (www.chantest.com)

ChanTest translates the most advanced Ion Channel, GPCR and Transporter technologies to provide safer, more effective medicines. By combining electrophysiology, molecular biology and cell culture including cell lines, stem cells and native cells ChanTest has developed biomarkers, reagents and services that greatly enhance drug discovery. The Company has alliances in which its technologies are integrated with medicinal, combinatorial and computational chemistry, animal models and clinical trials to provide modular or complete services along the drug development pathway. Since its inception in 1998, ChanTest has tested compounds for more than 500 global pharmaceutical and biotechnology companies. ChanTest's library of  ion channel cell lines, validated human stem cell-derived cardiomyocytes and  predictive nonclinical cardiac risk assessment program are  the most comprehensive available today. Because of ChanTest's seminal role in cardiac safety and its uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.

CONTACT: Kate Siver, +1-216-332-1665, info@chantest.com


'/>"/>
SOURCE ChanTest Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Meridian Labs Hires Investment Bank to Explore Strategic Opportunities
2. Health Revenue Assurance Associates Hires Valerie Rinkle as Vice President of Revenue Integrity Informatics
3. CSS Health Technologies Hires Industry Leader as New Senior Vice President of Sales
4. NHD Hires Ron Cronin as Executive Director
5. Millstone Medical Outsourcing Hires New Vice President Quality
6. Zimmer Holdings Names Christopher Begley to Board of Directors
7. Doug Pepper appointed as Chief Financial Officer at Cardiac Science
8. ADVENTRX Announces Appointment Of Chief Medical Officer
9. Accelr8 Appoints Steve Reichling Chief Financial Officer
10. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
11. Qforma Chief Technologist Honored as One of PharmaVOICE Magazines "100 Most Inspiring People in the Life Sciences"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Global Immunology ... market to drive long-term market growth Summary ... set of chronic disorders that affect 5–7% of ... terms of their symptoms and key patient demographics, ... of immune pathways and an inappropriate immune response. ...
(Date:2/4/2016)... VIEW, Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: ... management solutions to healthcare systems, today announced results for ... --> --> GAAP ... $130.3 million, up $5.1 million or 4.1% from the ... 7.2% from the fourth quarter of 2014. Revenue for ...
(Date:2/4/2016)... SAN DIEGO, Feb. 4, 2016  Aethlon Medical, ... creating affinity biofiltration devices to treat life-threatening diseases, ... fiscal 2016 ended December 31, 2015. ... short-term objectives set forth in our last quarterly ... that reinforce our long-term objective to establish the ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth quarter ... gathered at the La Valencia Hotel in San Diego, California to discuss changes ... the year’s most outstanding franchise, walking away with the coveted David Wright Award ...
(Date:2/5/2016)... ... 2016 , ... Pivot Point Consulting, a leading national Healthcare ... Services for HIT Implementation Support & Staffing report with an outstanding score of ... healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. , ...
(Date:2/5/2016)... Aliso Viejo, CA (PRWEB) , ... February 05, 2016 , ... ... Pro X. Move from on one drop zone to the next using Colorize's dynamic ... design complements any project. This package includes a 3D slideshow environment with 1 to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Calls Blacklist has just ... new user interface design and the developer has fixed known bugs within the app. ... to on their phone while not consuming any of their device’s battery power or ...
(Date:2/4/2016)... ... February 04, 2016 , ... Dr. Carol Francis and ... February 19-21, 2016, in Southern California . The International Hypnosis Federation 2016 Conference ... professional speakers, including Clinical Psychologist and Hypnotherapist Dr. Carol Francis (topics ...
Breaking Medicine News(10 mins):